Akums Drugs & Pharmaceuticals Ltd Q2 FY26 Earnings Analysis

- CDMO Business: - Expected mid-single-digit topline growth in FY26 due to continued soft API prices. - Rs. 300 crore annual revenue anticipated from the new EU CDMO contract starting April 2027, with full ramp-up possibly taking 2-3 years. - Five-year target of $100 million in exports, scaling up from the current $15 million in formulation exports. - Domestic Branded Formulations: - Expected to track IPM growth, with subdued 3-4% growth in Q1 seen as a one-off. - Anticipated better performance in subsequent quarters, maintaining overall yearly guidance. - International Branded Formulations: - High-teen growth expected for the full year despite weaker current quarter. - API Business: - Continued focus on global expansion (Europe, Africa, LATAM) and improved API pricing. - Single-digit growth expected amidst pricing pressure domestically. - Trade Generics: - Gradual rationalization expected; potential profitable units retained but no significant growth anticipated.

- **CDMO Business**: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%. - **Exports & European Business**: Aim to scale formulation exports from current $15 million to $100 million over the next five years, including a Rs. 300 crore contract starting FY28. - **Domestic Branded Formulation**: Growth expected to track or slightly outpace Indian Pharmaceutical Market (IPM) growth after a subdued Q1; full-year EBITDA margins steady around 18%. - **Trade Generics & API Segments**: Trade generics being rationalized to profitable units; API business loss reducing with global expansion focus, aiming for positive EBITDA by FY26. - **Overall**: Healthy EBITDA growth in Q1FY26 (+19% YoY), strong free cash flow, and prudent capital allocation support sustainable and profitable growth ahead.

- Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027. - Current ongoing capex projects include expansion at Baddi plant and utilization ramp-up at Haridwar facility. - Strategic inorganic investments focus on acquiring dosage form capabilities either within India or abroad to gain access to new markets and expand product portfolios. - Consideration for acquisitions targeting companies with strong R&D, quality manufacturing, and global market access, aiming to launch new products quickly. - The company is open to inorganic opportunities, supported by a healthy balance sheet and cash surplus of Rs. 1,518 crores. - Overseas expansion through European market plays including dossier filings and registration via Akums Healthcare UK, aiming to build a larger portfolio with exclusive marketing authorizations over time.

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript from the Q1FY26 earnings call. - The company mentions having a healthy balance sheet with a cash surplus of Rs. 1,518 crores and a positive free cash flow of Rs. 935 crores. - Discussion around capital expenditure (CAPEX) is ongoing, particularly for Jammu plant expansion and Baddi plant ramp-up, but this appears to be funded through existing cash and cash flows. - The company is open to inorganic growth opportunities and may deploy cash for acquisitions, specifically targeting dosage form capabilities or access to new markets. - No new debt or equity fundraising is indicated as an immediate plan; focus remains on utilizing existing cash reserves for growth and expansion.

- Akums Drugs & Pharmaceuticals has recently received a significant contract worth Rs. 300 crores linked to European markets. - They have other ongoing contracts of smaller values in progress. - Current export business run rate stands at Rs. 150 crores. - Over a five-year horizon, the company targets around $100 million in exports from the CDMO and international branded formulation segments combined. - The company is also working on expanding its European dossier approvals, including recently approved Rivaroxaban and upcoming dossiers like Dapagliflozin. - There is no explicit mention of the total outstanding order book value, but the pipeline appears strong with new product filings and contract onboarding, targeting scalable growth over 3-5 years.